These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37181975)

  • 1. Anti-spike Antibody Status in Pre-vaccinated Healthy Participants and Rheumatoid Arthritis Patients During the Third Wave of COVID-19.
    Eerike M; Sundaramurthy R; Gandham R; Sakthivadivel V; Amshala A; Priyadarshini R; Pyati AK; Patil P
    Cureus; 2023 Apr; 15(4):e37316. PubMed ID: 37181975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients.
    Furukawa H; Oka S; Higuchi T; Nakama M; Nagai N; Tohma S
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
    PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
    Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
    Front Immunol; 2022; 13():960001. PubMed ID: 36311767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.
    Kang ES; Oh JS; Lee EJ; Hong S; Ahn SM; Lee CK; Yoo B; Kim YG
    J Korean Med Sci; 2023 Apr; 38(14):e109. PubMed ID: 37038645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series.
    Zhao T; Shen J; Zhu Y; Tian X; Wen G; Wei Y; Xu B; Fu C; Xie Z; Xi Y; Li Z; Peng J; Wu Y; Tang X; Wan C; Pan L; Li Z; Qin D
    Front Public Health; 2022; 10():875558. PubMed ID: 35548080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of
    Higuchi T; Oka S; Furukawa H; Tohma S
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination.
    Bondareva M; Letz P; Karberg K; Schrezenmeier E; Semin I; Rincon-Arevalo H; Dörner T; Mashreghi MF; Stefanski AL; Kruglov AA
    J Autoimmun; 2022 Dec; 133():102918. PubMed ID: 36228431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
    Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
    Front Immunol; 2022; 13():909910. PubMed ID: 35784321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis.
    Wang P; Ni J; Chu YY; Chen QQ; Wu GC; Fang Y; Chen C; Zhang RD; Jiang LQ; Zhao Y; Fang X; He J; Wang DG; Wang GH; Pan HF
    Biomed Pharmacother; 2022 Jun; 150():112997. PubMed ID: 35486976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose.
    Le Moine C; Soyfoo MS; Mekkaoui L; Dahma H; Tant L
    Clin Exp Rheumatol; 2023 Jan; 41(1):82-87. PubMed ID: 35699073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.